// App-Quantinova.ai

TPS1104 : IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).

Researchers

Presenter

  • Leisha A. Emens

Principal Investigators

  • Sylvia Adams

  • Sherene Loi

  • Andreas Schneeweiss

  • Hope S. Rugo

  • Eric P. Winer

  • Carlos H. Barrios

  • Veronique Dieras

  • Juan de la Haba-Rodriguez

  • Luca Gianni

  • Stephen Y. Chui

  • Peter Schmid

Medical Centers

  • Johns Hopkins University, Baltimore, MD

  • New York University Cancer Institute, New York, NY

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • University Clinic Heidelberg, Heidelberg, Germany

  • University of California, San Francisco, San Francisco, CA

  • Dana-Farber Cancer Institute, Boston, MA

  • Latin American Cooperative Oncology Group, Porto Alegre, Brazil

  • Institut Curie, Paris Cedex, France

  • Medical Oncology Department University Reina Sofia Hospital. Biomedical Research Institute Maimonides, Cordoba, Spain

  • Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy

  • Genentech, Inc., South San Francisico, CA

  • University of Sussex, London, United Kingdom

Locations

  • Brazil

  • Italy

  • Germany

  • Spain

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Secondary liver cancer

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

  • Paclitaxel

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02425891

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved